Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Pharmaceutical Executive Digital Edition - December 2012

Articles in this issue

Related Content

Pharmaceutical Executive Daily: Hanmi Licenses HM17321 to Genentech

Hanmi Pharm Enters $2.3 Billion Licensing Agreement with Genentech for HM17321

Beyond Amyloid, Part One (of two): Tau and Microglia Redefine the Alzheimer’s Pipeline

Focusing on Asset Acquisition Over Building a Single Platform Technology

What the Peptide Advisory Vote Actually Means: Q&A with James LaValle

Trending on PharmExec

Beyond Amyloid, Part One (of two): Tau and Microglia Redefine the Alzheimer’s Pipeline

What the Peptide Advisory Vote Actually Means: Q&A with James LaValle

Hanmi Pharm Enters $2.3 Billion Licensing Agreement with Genentech for HM17321

Focusing on Asset Acquisition Over Building a Single Platform Technology

M&A Roundup: IntraGel & UroGen Sign Collaboration & Investment Agreements, Lupin & Tenpoint Form Commercialization Collaboration